Evidence map›Paper›PMID 41183201›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

A multivalent nanobody-drug conjugate to prevent and treat influenza virus infections.

Thibault J Harmand, Laura Pietrok, Helen Rich, Rhogerry Deshycka, Laney Flanagan, Aaron Accardo, Novalia Pishesha, Hidde L Ploegh

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Fc-engineering for improved cancer immunotherapy.Biochemical Society transactions · 2026
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Thibault J Harmand *Cerberus Therapeutics, Cambridge, MA 02139.ORCID 0000-0002-7582-0519
Laura Pietrok *Cerberus Therapeutics, Cambridge, MA 02139.
Helen RichCerberus Therapeutics, Cambridge, MA 02139.ORCID 0000-0001-9409-1553
Rhogerry DeshyckaCerberus Therapeutics, Cambridge, MA 02139.
Laney FlanaganCerberus Therapeutics, Cambridge, MA 02139.
Aaron AccardoCerberus Therapeutics, Cambridge, MA 02139.ORCID 0009-0000-2518-4430
Novalia PisheshaDivision of Immunology, Boston Children's Hospital, Boston, MA 02115.ORCID 0000-0002-8124-1265
Hidde L PloeghProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115.ORCID 0000-0002-1090-6071

Funding

Non-invasive imaging of the anti-tumor immune responseR01CA255216 · NCI · BOSTON CHILDREN'S HOSPITAL · PI PISHESHA, NOVALIA · 2021 to 2025
$2.9M
Armed nanobodies as anti-infectives and anti-tumor agentsR01AI182177 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI Hao Wu · 2024 to 2026
$1.6M
Gates Foundation INV-044751NCI NIH HHS R01 CA255216NIAID NIH HHS R01 AI182177
6 · The paper itself

Abstract

We describe the production and use of nanobody drug conjugates that comprise of VHH

Indexed as

Antiviral AgentsImmunoconjugatesInfluenza A virusOrthomyxoviridae InfectionsSingle-Domain AntibodiesZanamivirAnimalsFemaleHumansMiceMice, Inbred BALB CNeuraminidaseAntiviral AgentsImmunoconjugatesNeuraminidaseSingle-Domain AntibodiesZanamivirbioconjugateinfluenzananobody drug conjugates

Identifiers

PMID41183201
PMCPMC12625891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.